Journal Article

Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient.

M Gorschlüter, A Glasmacher, F Risse, B Klein, H U Klehr and J Mezger

in Nephrology Dialysis Transplantation

Volume 12, issue 3, pages 593-595
Published in print March 1997 | ISSN: 0931-0509
Published online March 1997 | e-ISSN: 1460-2385 | DOI: http://dx.doi.org/10.1093/ndt/12.3.593
Successful induction and consolidation therapy of acute myeloid leukaemia in a renal allograft recipient.

Show Summary Details

Preview

Immunosuppressed organ transplant recipients have a markedly increased risk of neoplasia. Among these malignancies acute myeloid leukaemia (AML) is rare. However, until now no case of successful chemotherapy has been reported. We present a 39-year-old male patient who developed AML (FAB M4 Eo) 4 years after renal transplantation and achieved a stable complete remission after induction therapy with standard dose cytarabine and daunorubicin. Remission duration is now 11 months. At present the transplant is functioning well after two additional courses of consolidation chemotherapy with high-dose cytarabine combined with mitoxantrone and idarubicine respectively. Cyclosporin A was given during all cycles of chemotherapy. We conclude that intensive chemotherapy in patients with AML following renal transplantation in good performance status is feasible.

Journal Article.  0 words. 

Subjects: Nephrology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.